{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"5"},{"groupId":"OG008","value":"21"}],"units":"Participants"}],"description":"For best overall response (BOR) and objective response rate (ORR), patients in the Efficacy Analysis Set (EAS) who did not have sufficient on-study tumor assessments to characterize response were included in the denominator when calculating BOR percent and ORR and were thus treated as non-responders.","groups":[{"description":"Part A Dose Level 1 NM21-1480-Q2W 0.15mg","id":"OG000","title":"Part A Dose Level 1 NM21-1480-Q2W 0.15mg"},{"description":"Part A Dose Level 2 NM21-1480-Q2W 1.5mg","id":"OG001","title":"Part A Dose Level 2 NM21-1480-Q2W 1.5mg"},{"description":"Part A Dose Level 3 NM21-1480-Q2W 8mg","id":"OG002","title":"Part A Dose Level 3 NM21-1480-Q2W 8mg"},{"description":"Part A Dose Level 4 NM21-1480-Q2W 24mg","id":"OG003","title":"Part A Dose Level 4 NM21-1480-Q2W 24mg"},{"description":"Part A Dose Level 5 NM21-1480-Q2W 80mg","id":"OG004","title":"Part A Dose Level 5 NM21-1480-Q2W 80mg"},{"description":"Part A Dose Level 6 NM21-1480-Q2W 240mg","id":"OG005","title":"Part A Dose Level 6 NM21-1480-Q2W 240mg"},{"description":"Part A Dose Level 7 NM21-1480-Q2W 800mg","id":"OG006","title":"Part A Dose Level 7 NM21-1480-Q2W 800mg"},{"description":"Part A2 NM21-1480-Q2W 1400mg","id":"OG007","title":"Part A2 NM21-1480-Q2W 1400mg"},{"description":"Part B NM21-1480-Q2W 800mg","id":"OG008","title":"Part B NM21-1480-Q2W 800mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The ORR for each given group (dose level, cohort, or arm) in the EAS are summarized according to RECIST 1.1 (and according to iRECIST), accompanied by a 2-sided exact 95% Clopper-Pearson confidence interval (CI).","reportingStatus":"POSTED","timeFrame":"From baseline to up to 12 weeks post last dose, up to 48 weeks.","title":"To Determine the Anti-tumor Activity (Best Overall Response) of NM21-1480 According to RECIST 1.1","type":"PRIMARY","unitOfMeasure":"Participants"}